عنوان
پدید آورنده
موضوع
رده
RC271.C5 M43 2018
RC271
.
C5
M43
2018
کتابخانه
محل استقرار
INTERNATIONAL STANDARD BOOK NUMBER
(Number (ISBN
3030105075
(Number (ISBN
3030105083
(Number (ISBN
9783030105075
(Number (ISBN
9783030105082
Erroneous ISBN
3030105067
Erroneous ISBN
9783030105068
TITLE AND STATEMENT OF RESPONSIBILITY
Title Proper
Mechanisms of drug resistance in cancer therapy /
General Material Designation
[Book]
First Statement of Responsibility
Mario Mandalà, Emanuela Romano, editors.
.PUBLICATION, DISTRIBUTION, ETC
Place of Publication, Distribution, etc.
Cham, Switzerland :
Name of Publisher, Distributor, etc.
Springer,
Date of Publication, Distribution, etc.
[2018]
PHYSICAL DESCRIPTION
Specific Material Designation and Extent of Item
1 online resource
SERIES
Series Title
Handbook of experimental pharmacology ;
Volume Designation
volume 249
INTERNAL BIBLIOGRAPHIES/INDEXES NOTE
Text of Note
Includes bibliographical references.
CONTENTS NOTE
Text of Note
Intro; Preface; Contents; Molecular and Pharmacological Mechanisms of Drug Resistance:An Evolving Paradigm; 1 Introduction; 2 Cellular Mechanism of Multidrug Resistance; 2.1 Drug Activation and Inactivation; 2.2 Expression of Drug Efflux Pumps; 2.3 DNA Damage Repair; 2.4 Deregulation of Apoptosis; 2.5 Alteration of Drug Target; 3 Conclusion; References; Major Physiological Signaling Pathways in the Regulation of Cell Proliferation and Survival; 1 Introduction; 2 Signaling Pathways Involved in the Regulation of Cell Proliferation
Text of Note
2 Resistance Mechanisms to EGFR-Driven NSCLC2.1 Resistance to First- and Second-Generation EGFR-TKIs; 2.1.1 Preclinical Evidence and Clinical Relevance of Resistance Mechanisms; 2.1.2 Detection of T790M Mutation; 2.1.3 Potential Strategies to Overcome Resistance; 2.2 Resistance to Third-Generation EGFR-TKIs; 2.2.1 Preclinical Evidence and Clinical Relevance of Resistance Mechanisms; 2.2.2 Potential Strategies to Overcome Resistance; 3 Resistance Mechanisms to ALK- and ROS1-Driven NSCLC; 3.1 Mechanisms of Crizotinib Resistance; 3.1.1 Mechanisms of Crizotinib Resistance Involving ALK and ROS1
Text of Note
2.1 Biological Regulation of Proliferation by mTOR/PI3K/Akt Signaling2.2 Ras/MAPK Signaling-Regulated Cell Proliferation, Differentiation, and Survival; 2.3 JAK/STAT Signaling in the Regulation of Cell Proliferation and Survival; 3 Signaling Interaction Network Between PI3K/Akt, Ras/MAPK, and JAK/STAT Axes; 4 Output Signals of Integrated Signaling Pathways; 4.1 Redundant Targeting of Shared Substrates in Cell Growth and Metabolism; 4.2 Differential Phospho-Regulation of Shared Substrates in Cell Proliferation and Survival; 5 Impact of Signaling Interaction Network in Clinical Cancer Therapies
Text of Note
4 Hypoxia Bridges Immune Tolerance and Angiogenesis in TME5 The Galectin-Glycan Axis: Linking Immunosuppression, Hypoxia, and Resistance to Anti-angiogenic Treatment; 5.1 Galectins as Extracellular Mediators of Angiogenesis; 5.2 Galectins as Mechanisms of Resistance to VEGF Blockade; 5.3 Targeting Gal1-N-Glycan Interactions Limits the Efficacy of Anti-VEGF Treatment; 6 Combinatorial Therapies: Anti-angiogenesis as a Partner of Immunotherapy; 7 Conclusions and Future Perspectives; References; Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer; 1 Introduction
Text of Note
6 Final RemarksReferences; Immune-Mediated and Hypoxia-Regulated Programs: Accomplices in Resistance to Anti-angiogenic Therapies; 1 Introduction; 2 Mechanisms of Resistance to Anti-angiogenic Therapies; 2.1 Expression of Alternative Pro-angiogenic Mediators; 2.2 Adaptation to Hypoxia; 3 Immune-Mediated Mechanisms of Resistance to Anti-angiogenesis; 3.1 Myeloid Cell-Dependent Resistance to Anti-angiogenic Therapies; 3.1.1 Pericytes; 3.1.2 CD11b+Gr1+ MDSCs; 3.1.3 Macrophages; 3.1.4 Dendritic Cells; 3.1.5 Mast Cells; 3.2 Lymphoid Cell-Dependent Resistance to Anti-angiogenic Therapies
0
8
8
8
8
SUMMARY OR ABSTRACT
Text of Note
A major objective of this book is to reveal unprecedented opportunities to understand and overcome drug resistance through the clinical assessment of rational therapeutic drug combinations and the use of predictive and prognostic biomarkers to enable patient stratification and tailor treatments. It offers to the readers an updated overview on the possible reasons of failure of new and promising therapeutic opportunities.
OTHER EDITION IN ANOTHER MEDIUM
International Standard Book Number
9783030105068
International Standard Book Number
9783030105082
TOPICAL NAME USED AS SUBJECT
Cancer-- Chemotherapy.
Drug resistance in cancer cells.
Cancer-- Chemotherapy.
Drug resistance in cancer cells.
HEALTH & FITNESS-- Diseases-- General.
MEDICAL-- Clinical Medicine.
MEDICAL-- Diseases.
MEDICAL-- Evidence-Based Medicine.
MEDICAL-- Internal Medicine.
(SUBJECT CATEGORY (Provisional
HEA-- 039000
MED-- 014000
MED-- 022000
MED-- 045000
MED-- 112000
MKG
MMG
DEWEY DECIMAL CLASSIFICATION
Number
616
.
99/4061
Edition
23
LIBRARY OF CONGRESS CLASSIFICATION
Class number
RC271
.
C5
Book number
M43
2018
PERSONAL NAME - ALTERNATIVE RESPONSIBILITY
Mandalà, Mario
Romano, Emanuela
ORIGINATING SOURCE
Date of Transaction
20200823082340.0
Cataloguing Rules (Descriptive Conventions))
pn
ELECTRONIC LOCATION AND ACCESS
Electronic name
مطالعه متن کتاب [Book]
Y
